Boston Scientific Corporation (BSX) Stock AnalysisBSXBoston Scientific Corporation

Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology and vascular therapies (ICVT), watchman, cardiac rhythm management, and electrophysiology. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Boston Scientific Corp is currently trading at $44.39, which is below the analyst price target of $48, suggesting potential upside. However, the stock has experienced a year-to-date decline of 53.13%, indicating significant volatility. The RSI is at 66.883, suggesting it is nearing overbought territory, which may limit short-term gains. Given the recent insider selling activity increasing by 755.62%, caution is warranted before making a buy decision.

24 analysts cover BSX: 18 rate it Buy, 6 Hold and 0 Sell. The average price target is 108.14.